CD - CROHN'S DISEASE
Clinical trials for CD - CROHN'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new CD - CROHN'S DISEASE trials appear
Sign up with your email to follow new studies for CD - CROHN'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New oral drug for inflammatory bowel disease enters first human tests
Disease control Recruiting nowThis early-stage trial tests BDHK-2009, an experimental tablet for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. The study involves 68 healthy adults aged 18 to 55 to see if the drug is safe and how the body handles it. Participants receive either a sin…
Matched conditions: CD - CROHN'S DISEASE
Phase: PHASE1 • Sponsor: Benethera (Shaoxing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New study pits two biologics against tough Crohn's complication
Disease control Recruiting nowThis study looks at two drugs, guselkumab and ustekinumab, in 100 adults with moderate-to-severe Crohn's disease that has caused narrowing (strictures) in the bowel. The goal is to see which drug better controls symptoms and improves imaging results over 52 weeks. Participants co…
Matched conditions: CD - CROHN'S DISEASE
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Rethinking routine drugs: could skipping allergy meds before IBD infusions be better?
Symptom relief Recruiting nowThis study looks at whether people with moderate-to-severe inflammatory bowel disease (IBD) need to take a steroid (dexamethasone) before each infliximab infusion to prevent allergic reactions. Researchers will compare those who get the steroid routinely with those who only get i…
Matched conditions: CD - CROHN'S DISEASE
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC